title: Effect of glucose-insulin-potassium infusion on myocardial damage due to percutaneous coronary revascularization.
abstract: Percutaneous coronary intervention has been known to cause myocardial damage as a result of microvascular dysfunction due to microembolization and microinfarction. Previous studies have shown that glucose-insulin-potassium (GIK) infusion decreases mortality in patients with acute myocardial infarction. Therefore, in this study, we aimed to investigate the effect of GIK infusion on myocardial damage due to percutaneous coronary revascularization. A total of 52 consecutive nondiabetic patients diagnosed with non-ST-elevation acute coronary syndrome and designated for elective percutaneous coronary intervention were randomized in a double-blind fashion into GIK and normal saline groups. GIK infusion (30% dextrose, 300 U insulin, and 60 mEq potassium chloride) at a dose of 1.5 ml/kg/hour was initiated 24 hours before the intervention and continuing during and until 1 hour after the intervention. Troponin I levels were recorded in venous blood samples before and 12 and 24 hours after the intervention. The increase in troponin I was significantly lower at 12 and 24 hours in the GIK group compared with those of the saline controls (p=0.022 and p=0.005, respectively). GIK infusion initiated 24 hours before coronary stenting for non-ST-elevation acute coronary syndrome resulted in less myocardial damage as determined by postprocedure troponin I levels.
authors.affiliation: Department of Cardiology, Ondokuz Mayis University Medical Faculty, Samsun, Turkey. drmeyaz@hotmail.com
authors.forename: Mustafa
authors.initials: M
authors.lastname: Yazici
authors.forename: Sabri
authors.initials: S
authors.lastname: Demircan
authors.forename: Kenan
authors.initials: K
authors.lastname: Durna
authors.forename: Erdogan
authors.initials: E
authors.lastname: Yasar
authors.forename: Zeydin
authors.initials: Z
authors.lastname: Acar
authors.forename: Mahmut
authors.initials: M
authors.lastname: Sahin
mesh_terms: D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D002314:Cardioplegic Solutions / Q000008:administration & dosage* / Q000627:therapeutic use; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D004311:Double-Blind Method; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000008:administration & dosage / Q000627:therapeutic use; D055502:Secondary Prevention; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood
chemical_list: D002314:Cardioplegic Solutions; D007328:Insulin; D019210:Troponin I; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium